Skip to content

Study · Observational study · 2024

3 results

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.

Yang W, Guo X, Lauand F, Li L, Fang H, Du Q, Kang L

Diabetes, obesity & metabolism3 Jan 2024Cited by 1 (Europe PMC)

PMID38172083 (opens in a new tab)DOI10.1111/dom.15414 (opens in a new tab)PepBankPUB-38172083
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Asian people with type 2 diabetes, iGlarLixi reduced HbA1c more than glargine across age and duration subgroups, including ≥65 years and ≥15 or ≥20 years of diabetes.

    In plain wordsIn Asian people with diabetes, adding lixisenatide lowered HbA1c more than glargine alone across age and disease-duration subgroups.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction across age and disease-duration subgroups
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HbA1c reductions were consistently greater with iGlarLixi versus iGlar or Lixi across all subgroups, including participants aged ≥65 years and those with T2D for ≥15 or ≥20 years.
    2 context sentences
    Summary · context
    To evaluate the effect of age and disease duration on the efficacy and safety of iGlarLixi versus insulin glargine 100 units/ml (iGlar) or lixisenatide (Lixi) alone in Asian people with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin ± oral antidiabetic…
    Summary · context
    In this post hoc analysis, the glycated haemoglobin (HbA1c) changes were assessed from baseline to week 24 (LixiLan-O-AP) or 30 (LixiLan-L-CN) in subgroups defined by baseline age (<65, ≥65 years) and duration of T2D.
  2. 02HumanObservational studyEfficacy outcome

    In Asian people with diabetes, more participants achieved HbA1c <7% (<53.0 mmol/mol) without weight gain or hypoglycaemia with iGlarLixi than glargine, regardless of age or disease duration.

    In plain wordsIn Asian people with diabetes, more participants reached the glucose target without weight gain or hypoglycaemia with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target without weight gain or hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Greater proportions of participants achieved HbA1c <7% (<53.0 mmol/mol) without weight gain or hypoglycaemia with iGlarLixi versus iGlar or Lixi, regardless of age or T2D duration.
    2 context sentences
    Summary · context
    To evaluate the effect of age and disease duration on the efficacy and safety of iGlarLixi versus insulin glargine 100 units/ml (iGlar) or lixisenatide (Lixi) alone in Asian people with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin ± oral antidiabetic…
    Summary · context
    In this post hoc analysis, the glycated haemoglobin (HbA1c) changes were assessed from baseline to week 24 (LixiLan-O-AP) or 30 (LixiLan-L-CN) in subgroups defined by baseline age (<65, ≥65 years) and duration of T2D.
  3. 03HumanObservational studySafety outcome

    In Asian people with diabetes, hypoglycaemia incidence was similar with iGlarLixi and glargine across most age and disease-duration subgroups.

    In plain wordsIn Asian people with diabetes, hypoglycaemia was similar with added lixisenatide and glargine alone across most subgroups.

    Peptide
    Lixisenatide
    Outcome
    No significant changeHypoglycaemia incidence
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hypoglycaemia incidence was similar with iGlarLixi versus iGlar across most subgroups; the incidence of gastrointestinal disorders was lower with iGlarLixi versus Lixi in all subgroups.
    2 context sentences
    Summary · context
    To evaluate the effect of age and disease duration on the efficacy and safety of iGlarLixi versus insulin glargine 100 units/ml (iGlar) or lixisenatide (Lixi) alone in Asian people with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin ± oral antidiabetic…
    Summary · context
    In this post hoc analysis, the glycated haemoglobin (HbA1c) changes were assessed from baseline to week 24 (LixiLan-O-AP) or 30 (LixiLan-L-CN) in subgroups defined by baseline age (<65, ≥65 years) and duration of T2D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.